Alzinova: The Aducanumab Thriller (From an Alzinova Perspective)
Research Note
2020-11-05
08:30
Redeye summarizes the regulatory news with Biogen's biologics candidate, aducanumab, which caused a hefty reaction in the Alzinova share.
AH
Anders Hedlund
Disclosures and disclaimers